Practice teaching course on head and neck cancer management
29-30 September 2017 - Saint-Priest en Jarez, France
GENERAL INFORMATION
Overview
Head and neck squamous cell carcinoma (HNSCC) is a group of extremely heterogeneous tumors. Surgery, radiation and chemotherapy in multiple combinations are used to manage HNSCC, depending on the TNM stage and primary site. The majority of patients present with locally advanced stage disease and require multimodal treatment. Managing HNSCC will likely to be subject to change in the near future, moving from treatment as a single disease to tailoring therapy based on both patient and tumour characteristics. This educational activity offers the chance to review treatment alternatives for head and neck cancer while illuminating emerging knowledge and controversy within the multidisciplinary management of locally advanced head and neck cancer patients. Concrete interaction between the multidisciplinary team and attendees will be supported through clinical case discussions and practical sessions focusing on treatment planning and delivery.

Learning objectives
At the end of this educational practice teaching course, the attendee will be able to:

• evaluate the benefit of multidisciplinary teams in the treatment of head and neck cancer
• summarize general principles of surgery, radiotherapy and systemic therapies for the treatment of head and neck cancer patients
• discuss how to optimize and refine therapeutic index in radiation therapy

Target audience
This programme is targeted at medical oncologists and radiation oncologists involved in the care of patients with advanced head & neck malignancies who wish to enhance their knowledge of clinical medicine and become aware of the latest advances in medical research.
CME Provider
EXCEMED is a non-profit foundation dedicated, since the last four decades, to the development of high-quality medical education programmes all over the world. EXCEMED adheres to the guidelines and standards of the European Accreditation Council for Continuing Medical Education (EACCME®) which states that continuing medical education must be balanced, independent, objective and scientifically rigorous.

Continuing Medical Education
EXCEMED (www.excemed.org) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) to provide the following CME activity for medical specialists. The EACCME® is an institution of the European Union of Medical Specialists (UEMS), www.uems.net

An application has been made to the EACCME® for CME accreditation of the “Practice teaching course on head and neck cancer management” to be held on 29-30 September 2017 in Saint-Priest en Jarez, France. Each medical specialist should claim only those credits that he/she actually spent in the educational activity. EACCME® credits are recognized by the American Medical Association (AMA) towards the Physician’s Recognition Award (PRA). To convert EACCME® credit to AMA PRA category 1 credit, please contact the AMA.

EXCEMED adheres to the principles of the Good CME Practice group (gCMEp).
Venue
This practice teaching course takes place at the:
Cancer Institute Lucien Neuwirth
108 bis, avenue Albert Raimond
Saint-Priest en Jarez Cedex, France

Language
The official language of this practice teaching course is English.

CME Provider
EXCEMED - Excellence in Medical Education
Programme Manager: Michela Fiuzzi
T +39 06 420413 252 - F +39 06 420413 677
michela.fiuzzi@excemed.org

Medical Advisor: Cristina Raimondi
cristina.raimondi@libero.it

For any logistic inquiry, please contact:
Meridiano Congress International
Senior Event Manager: Concetta Di Palma
T +39 06 88 595 226 - F +39 06 88595 234
concetta.dipalma@meridiano.it
Aiming for excellence
One of the factors we depend on for crafting high-quality learning experiences is our Learning Effectiveness Programme. Participants are asked to submit a Pre-event, Post-event and Follow-up survey which assess their learning trajectory, satisfaction with the scientific programme, sense of confidence in the subject matter and possible commitment to change in clinical practice. Participant feedback helps us enormously and we thank everyone in advance for their cooperation. Those who complete the surveys are eligible to receive their CME certificate after the event.

Our programme allows you to add your voice to the conversation
Express your opinion, pose questions and engage with faculty. Our objective is to help you get the most from your learning experience with us. We wish you a unique learning experience.

Learning: it’s also fun and games
During the working groups, challenge yourself by completing the interactive clinical case on the iPad. Confront your subgroup’s opinions through gaming: make strategic decisions based on clinical information and see if you can provide the best option. Understanding, treating and managing advanced head and neck malignancies are brought together in this digital approach.

Live graphic recording
Some lectures will also be supported by Live Graphic Recording, an innovative illustrated reportage technique featuring a live artist who chronicles the proceedings using keywords, images, charts and diagrams. Think of it as a visual summary to creatively and symbolically help participants retain key points.
Chair

Nicolas Magné
Cellular and Molecular Radiotherapy Laboratory
Institut de Physique Nucléaire de Lyon (IPNL)
Faculté de Médecine Lyon-Sud
Lyon, France
Department of Radiation Oncology
Lucien Neuwirth Cancer Institute
Saint-Priest en Jarez, France

Faculty

Jean-Baptiste Guy
Cellular and Molecular Radiotherapy Laboratory
Institut de Physique Nucléaire de Lyon (IPNL)
Faculté de Médecine Lyon-Sud
Lyon, France

Nicolas Magné
Cellular and Molecular Radiotherapy Laboratory
Institut de Physique Nucléaire de Lyon (IPNL)
Faculté de Médecine Lyon-Sud
Lyon, France
Department of Radiation Oncology
Lucien Neuwirth Cancer Institute
Saint-Priest en Jarez, France
Chloé Rancoule  
Radiotherapy department  
Lucien Neuwirth Cancer Institute  
Saint-Priest-en-Jarez, France

Alexis Vallard  
Department of Radiation Oncology  
Lucien Neuwirth Cancer Institute  
Saint-Priest-en-Jarez, France

EXCEMED designed this programme in partnership with Prova Education.
Friday, 29 September 2017

08.45  Opening and introduction

Session I  Multidisciplinary care in HNSCC

09.00  Visit of the Lucien Neuwirth Cancer Institute
        N. Magné (France)

10.30  Coffee break

Lectures will be conducted by N. Magné (France)

11.00  L1: Role of MDT and Impact on therapeutic strategies

11.30  L2: Multidisciplinary care in practice

12.00  L3: International guidelines for the treatment of HNSCC
        This lecture will be graphically recorded

12.40  L4: Latest Breaking News in HNSCC
        J.-B. Guy (France)

13.00  Lunch

Legend

L: Lecture  Site visit  Q&A  Graphic recording
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker (Country)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00</td>
<td>L5:</td>
<td>Locally advanced HNSCC</td>
<td>N. Magné (France)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.40</td>
<td></td>
<td>i-Solve clinical case</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Interactive clinical case solving</td>
<td></td>
</tr>
<tr>
<td>15.10</td>
<td></td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>15.25</td>
<td>L6:</td>
<td>Recurrent/metastatic HNSCC</td>
<td>N. Magné (France)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td></td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>16.00</td>
<td>L7:</td>
<td>Optimize and refine therapeutic index in radiation therapy</td>
<td>C. Rancoule (France)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.20</td>
<td>L8:</td>
<td>Management of radiation-related complications and supportive care</td>
<td>J.-B. Guy (France)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.40</td>
<td></td>
<td>Practice session on toxicity management</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>This practice session will be graphically recorded</td>
<td></td>
</tr>
<tr>
<td>17.30</td>
<td></td>
<td>End of the first day</td>
<td></td>
</tr>
</tbody>
</table>

**Legend**

L: Lecture  
: Interactive clinical case  
Q&A: Q&A  
: Practice session  
: Graphic recording
### Saturday, 30 September 2017

**Session III** Cellular and molecular radiotherapy

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td><strong>L9:</strong> The molecular biology of head and neck cancers</td>
<td>N. Magné (France)</td>
</tr>
<tr>
<td>09.30</td>
<td><strong>L10:</strong> Radiosensitivity and radioresistance of head and neck cancers: biological angle</td>
<td>C. Rancoule (France)</td>
</tr>
<tr>
<td>10.00</td>
<td><strong>L11:</strong> Targeting head and neck tumor stem cells to overcome resistance to therapy</td>
<td>A. Vallard (France)</td>
</tr>
<tr>
<td>10.45</td>
<td>Wrap-up</td>
<td></td>
</tr>
<tr>
<td>11.00</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>11.15</td>
<td><strong>L12:</strong> Overview on the current/open research programmes at the “Radiobiologie Cellulaire et Moléculaire Institut de Physique Nucléaire de Lyon”</td>
<td>J.-B. Guy (France)</td>
</tr>
<tr>
<td>12.15</td>
<td><strong>Journal club</strong></td>
<td>A. Vallard (France)</td>
</tr>
<tr>
<td>13.15</td>
<td>End of the course</td>
<td></td>
</tr>
</tbody>
</table>

**Legend**

- **L:** Lecture
- **Q&A:** Q&A
- **Wrap-up:** Wrap-up
- **Journal club:** Journal club
EXCEMED adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programmes awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the programme (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the programme and all programme-related materials neither imply an endorsement nor a recommendation on the part of EXCEMED. All presentations represent solely the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

Jean-Baptiste Guy
Declared no potential conflict of interest.

Nicolas Magné
Declared the receipt of consultation fee and honoraria from Merck and Takeda.

Chloé Rancoule
Declared no potential conflict of interest.

Alexis Vallard
Declared no potential conflict of interest.
All EXCEMED programmes are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of EXCEMED. This programme is made possible thanks to an educational grant received from Merck KGaA, Darmstadt, Germany and San Raffaele Hospital, Milan, Italy.
Improving the patient’s life through medical education

www.excemed.org